Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
about
Recombinant human activated protein C for severe sepsis in neonatesHuman recombinant activated protein C for severe sepsisHuman recombinant protein C for severe sepsis and septic shock in adult and paediatric patientsHuman recombinant activated protein C for severe sepsisHuman recombinant activated protein C for severe sepsisRecombinant human activated protein C for severe sepsis in neonatesDrotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.The effect of activated protein C on experimental acute necrotizing pancreatitisA meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis.T-cell-mediated immunity and the role of TRAIL in sepsis-induced immunosuppressionDesigning trials and deciding on therapy in complex diseases: what can we do to improve?Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis.Systems engineering medicine: engineering the inflammation response to infectious and traumatic challenges.Treatment with activated protein C (aPC) is protective during the development of myocardial fibrosis: an angiotensin II infusion model in miceAn integrated transcriptome and expressed variant analysis of sepsis survival and death.Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study.Activated protein C in septic shock: a propensity-matched analysisCoagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.Barriers to glucose control in the intensive care unit.Emerging drugs for the treatment of sepsis.Treatment options for severe sepsis and septic shock.Effects of anticoagulant strategies on activation of inflammation and coagulation.Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center.A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice.Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant.Activated protein C in sepsis: the promise of nonanticoagulant activated protein C.Emerging drugs in sepsis.Arterial thrombosis in the context of HCV-associated vascular disease can be prevented by protein C.Effect of activated protein C in second intention healing of equine distal limb wounds: a preliminary study.Recombinant activated protein C usage in Scotland: a comparison with published guidelines and a survey of attitudes.Vascular endothelial growth factor, as compared with placental growth factor, is increased in severe sepsis but not in organ failure
P2860
Q24200439-2804EAB1-E9C4-4BF2-BD3C-F5A5E7A1C3CCQ24201123-72B54ED3-FF49-4C18-AE2E-FBA0459EEAB6Q24202128-9FC38EDE-0DC6-4383-B460-6AAADC31D9F1Q24235181-F8A57E29-863F-44C1-9BC4-27428879D6EFQ24242859-22965D4F-59A1-4F4D-A36A-E8F41C08E46AQ24246064-545BAD87-F22B-404C-898E-F7EB8BD6BAFBQ24810495-62CB68F7-F793-487F-9485-BA7E96BD7D3EQ24811564-7843ACC0-3930-4E31-931B-546C8D9A8738Q24816510-4CC76697-9078-430A-A5FF-454DDE909E36Q26823892-9742ADAD-425B-4A5A-9825-3E80CF255C34Q30437619-A109F93E-9961-4CA2-8667-3E1B49DE64BBQ33338424-E2D855EB-5FF8-4F9A-AF51-A6994A283A4CQ33891519-83C3100D-07EB-4273-8143-41D4073CD297Q34429743-AD4AC0CD-21AC-4311-BC8D-A30FEBDC8B42Q34762245-009C6D50-74AF-4E65-BA2C-527A5CD53A4BQ35558328-1E436D9D-1D10-4C9D-B784-6913F77C51D7Q35559424-29767E2B-3CB4-406A-B8DD-8AFC7BB1FF73Q36349735-1E8547AF-FCE1-4D0A-BA46-A8923A61D049Q36390908-E62AFB0F-A2DA-4632-839D-E11ECCCC1922Q36407391-773C750C-476D-4878-8429-7FF6F004EFE1Q36505487-2A503D83-E822-4902-A1AB-4EA660B2E915Q36842724-B4A6462D-FD34-4196-AA41-030AAD7A9DBDQ36919457-E5416E0A-4A19-4ECC-A578-6D13361D8609Q37002272-3F1D20EF-D1F5-491F-921D-85CD3BBA25B2Q37237490-6D5D1A0F-4DFC-4866-88C9-EAE542C56775Q37241529-D6B1AED0-FEB9-40A4-9AE9-6DEC5E1E919EQ37670186-6186E1E5-8E04-447C-BDAD-8AE82095A47AQ40711044-F60E1784-8E29-43FA-BF8D-C4A28B54B0BDQ48127917-BCC1BE08-A7BE-49CB-8F52-D1C51ECA2AE6Q48221454-5DD4D71E-5386-4B46-8B69-A59C362DFBCBQ57767295-C646C84C-3491-4FC2-94F6-3A5B80FE5612
P2860
Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Extended evaluation of recombi ...... (activated) in severe sepsis.
@en
Extended evaluation of recombi ...... (activated) in severe sepsis.
@nl
type
label
Extended evaluation of recombi ...... (activated) in severe sepsis.
@en
Extended evaluation of recombi ...... (activated) in severe sepsis.
@nl
prefLabel
Extended evaluation of recombi ...... (activated) in severe sepsis.
@en
Extended evaluation of recombi ...... (activated) in severe sepsis.
@nl
P2093
P356
P1433
P1476
Extended evaluation of recombi ...... (activated) in severe sepsis.
@en
P2093
Arthur P Wheeler
Benjamin D Margolis
Extended Evaluation of Recombinant Human Activated Protein C United States Investigators
Gordon R Bernard
Harvey M Shanies
Howard Levy
Theressa J Wright
P304
P356
10.1378/CHEST.125.6.2206
P407
P577
2004-06-01T00:00:00Z